Could miltefosine be used as a therapy for toxoplasmosis?

Experimental Parasitology

Volumn 157, Issue , 2015, Pages 12-22

  Eissa, Maha M ^a   Barakat, Ashraf M A ^b   Amer, Eglal I ^a   Younis, Layla K ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Chronic toxoplasmosis; Electron microscopy; Me49 strain; Miltefosine; RH strain; Toxoplasma gondii

Indexed keywords

MILTEFOSINE; SULFADIAZINE; ANTIPROTOZOAL AGENT; PHOSPHORYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CYST (RESTING STAGE); DRUG EFFICACY; DRUG POTENCY; HISTOPATHOLOGY; MOUSE; NANOTECHNOLOGY; NONHUMAN; PARASITE LOAD; PARASITE VIRULENCE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SURVIVAL RATE; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; INFECTIOUS ENCEPHALITIS; LIVER; MORTALITY; PARASITOLOGY; PATHOLOGY; SPLEEN; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; ULTRASTRUCTURE;

TOXOPLASMA; TOXOPLASMA GONDII;

ANIMALS; ANTIPROTOZOAL AGENTS; BRAIN; DISEASE MODELS, ANIMAL; INFECTIOUS ENCEPHALITIS; LIVER; MICE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; PHOSPHORYLCHOLINE; SPLEEN; SURVIVAL RATE; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

EID: 84938497069     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2015.06.005     Document Type: Article

References (66)

1. Abdel Wahab R.M., Morsy T.A., Bahgat A.B., Abdel Rahim M.I., Eissa M.H., Alfy Y.E. The histopathological picture of concomitant infection with Leishmania major and Toxoplasma gondii in albino mice. J. Egypt. Soc. Parasitol. 1989, 19:1-13.
2. Araujo F., Suzuki Y., Remington J. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. Eur. J. Clin. Microbiol. Infect. Dis. 1996, 15:394-397.
3. Aspinall T.V., Joynson D.H., Guy E., Hyde J.E., Sims P.F. The molecular basis of sulphonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J. Infect. Dis. 2002, 185:1637-1643.
4. Barakat A.M.A., Sylvia O.A. The effect of clindamycin and sulfadiazine on experimental murine model with acute toxoplasmosis. Assiut Vet. Med. J. 2010, 56(127):302-315.
5. Baron B.W., Hyjek E., Gladstone B., Thirman M.J., Baron J.M. PDCD2, a protein whose expression is repressed by BCL6,induces apoptosis in human cells by activation of the caspasecascade. Blood Cells Mol. Dis. 2010, 45:169-175.
6. Barratt G., Saint-Pierre-Chazalet M., Loiseau P.M. Cellular transport and lipid interactions of miltefosine. Curr. Drug Metab. 2009, 10:247-255.
7. Bartke N., Hannun Y.A. Bioactive sphingolipids: metabolism and function. J. Lipid Res. Suppl. 2009, 50:91-96.
8. Blaha C., Duchene M., Aspock H., Walochnik J. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and susceptible strains of Trichomonasvaginalis. J. Antimicrob. Chemother. 2006, 57:273-278.
9. Berman J. Miltefosine to treat leishmaniasis. Expert Opin. Pharmacother. 2005, 6:1381-1388.
10. Breiser A., Kim D., Fleer E., et al. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 1987, 22:925-926.
11. Brown D., Superti-Furga G. Rediscovering the sweet spot in drug discovery. Drug Discov. Today 2003, 8:106-107.
12. Chaudhary K., Darling J.A., Fohl L.M., Sullivan W.J., Donald R.G., Pfefferkorn E.R., et al. Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii. J. Biol. Chem. 2004, 279:31221-31227.
13. Chaturvedi D., et al. Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Chem. Soc. Rev. 2010, 39:435-454.
14. Chew W.K., Segarra I., Ambu S., Mak J.W. Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis. Antimicrob. Agents Chemother. 2012, 56(4):1762-1768.
15. Choubey V., Maity P., Guha M., et al. Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism. Antimicrob. Agents Chemother. 2007, 51:696-706.
16. Costa I.N., Angeloni M.B., Santana L.A., Barbosa B.F., Silva M.C., Rodrigues A.A., et al. Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae). Placenta 2009, 30(10):884-890.
17. Cugh P., Bradel-Tretheway B., Monteiro-Filho C.M.R., Planalles V., Maggirwar S.B., Dewhurst S., Kim B. Akt inhibitors as an HIV-I infected macrophagespecific anti-viral therapy. Retrovirology 2008, 5. (art. no. 11).
18. Degerli K., Kilimcioglu A.A., Kurt O., Tamay A.T., Ozbilgin A. Efficacy of azithromycin in a murine toxoplasmosis model, employing a Toxoplasma gondiistrain from Turkey. Acta Trop. 2003, 88:45-50.
19. Dissous C., Grevelding C.G. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective?. Trends Parasitol. 2011, 27:59-66.
20. Djakovic D., Milenkovic T. Murine model of drug-induced reactivation of Toxoplasma gondii. Acta Protozool. 2001, 40:99-106.
21. Djurkovi-Djakovi O., Milenkovi V., Nikoli A., Bobi B., Gruji J. Efficacy of atovaquone combined with clindamycin against murineinfection with a cystogenic (Me49) strain of Toxoplasma gondii. J. Antimicrob. Chemother. 2002, 50:981-987.
22. Eissa M.M., El-Azzouni M.Z., Amer E.I., Baddour N.M. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int. J. Parasitol. 2011, 41:235-242.
23. Eissa M.M., El-Bardisy S., Tadros M. Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts supported by scanning electron microscopy. Parasit. Vectors 2011, 4(73).
24. Eissa M.M., Amer E.I. Giardia lamblia: a new target for miltefosine. Inter J. Parasitol. 2012, 42:443-452.
25. Eissa M.M., El-Azzouni M.Z., Mady R.F., Fathy F.M., Baddour N.M. Initial characterization of an autoclaved Toxoplasma vaccine in mice. Exp. Parasitol. 2012, 131:310-316.
26. El-Temsahy M., El-Kerdany E.D., Abou-Shamaa A.M. Study of the role of antioxidants in experimental toxoplasmosis. J. Med. Res. Inst. 2002, 23:59-69.
27. Fox B.A., Gigley J.P., Bzik D.J. Toxoplasma gondii lacks the enzymes required for denovo arginine biosynthesis and arginine starvation triggers cyst formation. Int. J. Parasitol. 2004, 34:323-331.
28. Hayat M.A. Principles and Techniques of Electron Microscopy: Biological Applications 2000, VNR Company, New York, USA.
29. Holmes M., Crater A.K., Dhudshia B., Thadani A.N., Ananvoranich S. Toxoplasma gondii: Inhibitory activity and encystation effect of securinine and pyrrolidine derivatives on Toxoplasma growth. Exp. Parasitol. 2011, 127:370-375.
30. Hopkins A.I., Witty M.J., Owa S. Mission possible. Nature 2007, 449:166-169.
31. Innes E.A. Vaccination against Toxoplasma gondii: an increasing priority for collaborative research?. Expert Rev. Vaccines 2010, 9:1117-1119.
32. Jones J.L., Kruszon-Moran D., Sanders-Lewis K., Wilson M. Toxoplasma gondii infection in the United States, 1999-2004, decline from the prior decade. Am. J. Trop. Med. Hyg. 2007, 77:405-410.
33. Kim K., Weiss L.M. Toxoplasma gondii: the model apicomplexan. Int. J. Parasitol. 2004, 34:423-432.
34. Ku J., Holec-Gasior L., Hiszczynska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev. Vaccines 2009, 8:791-808.
35. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nunez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G. Classification of cell death: recommendations of the nomenclature committee on cell death. Cell Death Differ. 2009, 16:3-11.
36. Lang C., Grob U., Luder C.G.K. Subversion of innate and adaptative immune responses by Toxoplasma gondii. Parasitol. Res. 2007, 100:191-203.
37. Llull D., Rivas L., Garcia E. In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci. Antimicrob. Agents Chemother. 2007, 51:1844-1848.
38. Lux H., Heise N., Klenner T., Hart D., Opperdoes F.R. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. 2000, 111:1-14.
39. Marschner N., Kötting J., Eibl H., et al. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother. Pharmacol. 1992, 31:18-22.
40. Matuschka F.R. The effect of sulfomethoxypyrazine-pyrimethamine therapy on the fine structure of Toxoplasma gondii-cysts in the brain of Mastomys natalensis. Scanning and transmission electron microscopical investigations. Zentralbl Bakteriol. Orig. A 1977, 238(3):419-429.
41. McFadden D.C., Tomavo S., Berry E.A., Boothroyd J.C. Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol. Biochem. Parasitol. 2000, 108:1-12.
42. McFadden D.C., Boothroyd J.C. Cytochrome b mutation identified in a decoquinate-resistant mutant of Toxoplasma gondii. J. Eukaryot. Microbiol. 1999, 46:81S-82S.
43. Mcleod R., Frenkel J.K., Estes R.G., Mack D.G., Eisenhanuer P.B., Gibori G. Subcutaneous and intestinal vaccination with tachyzoites of Toxoplasma gondii and acquisition of immunity to per oral and congenital Toxoplasma challenge. J. Immunol. 1988, 140:1632-1637.
44. McLeod R., Khan A.R., Noble G.A., Latkany P., Jalbrzikowski J., Boyer K. Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. Pediatr. Infect. Dis. J. 2006, 25(3):270-272.
45. Montoya J.G., Liesenfeld O. Toxoplasmosis. Lancet 2004, 363:1965-1976.
46. Montoya J.G., Remington J.S. Management of Toxoplasma gondii infection during pregnancy. Clin. Infect. Dis. 2008, 47:554-566.
47. Nazila A., Okombo J., Becker R.P., Lang T., Niehues T. Anticancer agents against malaria: time to revisit?. Trends Parasitol. 2010, 26:125-129.
48. Ni Nyoman A.D., Lüder C.G.K. Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agent: a proof-of-concept study. Apoptosis 2013, 18:665-680.
49. Otto R.R. Hexadecylphosphocholin (Miltefosin) und seine antiparasitäre Wirkung gegen Toxoplasma gondii in Zellkultur und im Mausmodell 2011, Department of Medicine - Charité - University Medicine, Berlin, PDF-Datei von FUDISS_thesis_000000022074.
50. Polat Z.A., Obwaller A., Vural A., Walochnik J. Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. Parasitol. Res. 2012, 110(2):515-520.
51. Parussini F., Coppens I., Shah P.P., Diamond S.L., Carruthers V.B. Cathepsin L occupies a vacuolar compartment and is a protein maturase within the endo/exocytic system of Toxoplasma gondii. Mol. Microbiol. 2010, 76:1340-1357.
52. Que X., Engel J.C., Ferguson D., Wunderlich A., Tomavo S., Reed S.L. Cathepsin Cs are key for the intracellular survival of the protozoan parasite, Toxoplasma gondii. J. Biol. Chem. 2007, 282:4994-5003.
53. Rana S., Gupta K., Gomez J., Matsuyama S., Chakrabarti A., Agarwal M.L., Agarwal A., Agarwal M.K., Wald D.N. Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells. FASEB J. 2010, 24:2126-2134.
54. Romand S., Pudney M., Derouin F. In vivo and in vitro activities of hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob. Agents Chemother. 1993, 37:2371-2378.
55. Schmidt D.R., Hogh B., Andersen O., Hansen S.T., Dalhoff K., Petersen E. Treatment of infants with congenital toxoplasmosis: tolerability plasma concentrations of sulfadiazine and pyrimethamine. Eur. J. Pediatr. 2006, 165:19-25.
56. Schuster F.L., Guglielmo B.J., Visvesvara G.S. In vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J. Eukaryot. Microbiol. 2006, 53:121-126.
57. Seifert K., Duchaene M., Werndorfer W.H. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob. Agents Chemother. 2001, 45:1505-1510.
58. Sinai A.P., Payne T.M., Carmen J.C., Hardi L., Watson S.J., Molestina R.E. Mechanisms underlying the manipulation of host apoptotic pathways by Toxoplasma gondii. Int. J. Parasitol. 2004, 34:381-391.
59. Sindermann H., Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:S17-S20.
60. Sumyuen M., Garin Y., Derouin F. Effect of immunosuppressive drug regimens on acute chronic murine toxoplasmosis. Parasitol. Res. 1996, 82:681-686.
61. Urbina J.A. Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:S9-S16.
62. Van Blitterswijk W.J., Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr. Pharm. Des. 2008, 14:2061-2074.
63. Walochnik J., Duchene M., Seifert K., Obwaller A., Hottkowitz T., Wiedermann G., Eibl H., Aspock H. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob. Agents Chemother. 2002, 46:695-701.
64. Webster D., Umar I., Kolyvas G., Bilbao J., Guiot M.C., Duplisea K., Qvarnstrom Y., Visvesvara G.S. Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier. Am. J. Trop. Med. Hyg. 2012, 87:715-718.
65. Widmer F., Wright L.C., Obando D., Handke R., Ganendren R., Ellis D.H., Sorrell T.C. Hexadecylphosphocholine (miltefosine) has a broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob. Agents Chemother. 2006, 50:414-421.
66. Wieder T., Reutter W., Orfanos C.E., Geilen C.C. Mechanisms of action of phospholipid analogs as anticancer compounds. Prog. Lipid. Res. 1999, 38:249-259.